Alexion Pharmaceuticals is set to enter the COVID-19 drug development race in the next few days via a single-arm, 100-patient Phase II trial investigating Soliris (eculizumab), a source familiar with the trial has revealed to GlobalData.

If this Phase II trial delivers a positive risk-benefit ratio, it would then pave the way for a 300-patient, randomised trial that would start shortly after. The Phase II trial will have sites in the US and Europe and is targeted to run for two weeks and the trial will have a primary endpoint looking into patient mortality between three-to-four weeks, the source said.

Read the full story

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData